



1Q 2008 Results

Natraceutical Group increases EBITDA by 25% and net profit by 40% in the first quarter of 2008

The company increases profitability,
while strengthening its plans of expansion

Valencia, 24th April, 2008. - Natraceutical Group, a biotechnology multinational leader in Europe in the research and development of functional ingredients, active principles and food supplements, posted an EBITDA of 7.3 million euros in the first quarter of 2008, which represents an increase of 25% with respect to the 5.8 million euros obtained in the same period last year.

Regarding revenues, the Group reached 47.25 million euros (as opposed to 45.01 million euros in the first quarter of 2007), reaching a profitability of 15.4% for the first three months of year 2008 (EBITDA margin over sales), as opposed to a profitability of 12.8% in the same period of the previous exercise.

The Group's net profit in the first quarter of 2008 reached the figure of 3.7 million euros, a growth of 40.28% compared to the first quarter of 2007.

Following the company's strategy from last year, in 2008 Natraceutical continues improving its profitability as opposed to the sales volume, especially with respect to the replacement of those products in the ingredients division that do not allow the company to maintain significant profitability rates.

Insofar, at the end of 2007, the company gave up the production of synthetic caffeine, as a result of the evolution of the market trends, which are experiencing an increase in the consumption of functional and natural products. The company decided then to concentrate its activity in caffeine production in that of natural caffeine, whose margins are significantly higher. Without considering the impact of this fact, the organic growth of the Group's sales was of 12.5%.

Thereby, in first quarter of 2008, the Ingredients division reached the figure of 24.96 million euros in sales and 3.37 million euros in EBITDA, the latter representing a growth of 39% with respect to the same period of the previous exercise, thus granting the division a profitability of 13.5% versus a percentage of 10% in the first quarter of 2007.

All in all, the nutritional supplements division reaches 22.28 million euros in sales and 5 million euros in EBITDA, which implies a profitability of 22.4% versus a percentage of 20% in the first quarter of 2007.



For the present financial year, Natraceutical Group foresees a new strong investment in publicity and marketing in order to consolidate Forté Pharma as a Pan-European brand (where the company is already present in France, Belgium, The Netherlands, Luxembourg, Switzerland, Austria, Spain, Portugal and beginning in Italy), as well as for the launching of new products that continue balancing the proportion of the different ranges (slimming, beauty, health and fitotherapy), at the moment still seasonal because of the slimming range. For that reason, Natraceutical Group alerts that the results of the first quarter, especially with respect to the EBITDA, do not have to be extrapolated linearly throughout the year because of the impact of these investments in the profit and loss account of the complete year.

Natraceutical Group

The biotech multinational Natraceutical Group, with headquarters in Valencia and a world wide presence, leads the European market in research and development of functional food, active ingredients and food supplements of natural origin.

The continuous advances in its R&D department allowed the Group in 2006 to diversify its business and expand its activity from the production of functional ingredients and active principles for food, cosmetics and pharma, to the final consumer via the acquisition of Laboratoires Forté Pharma, specialized in food supplements for slimming, health and beauty, and a leader in the French market in the former.

The international growth plan for this business area considers the creation of a Pan-European umbrella brand in a two-years period, and the subsequent development of several projects very closely related to this division.

With production plants in Spain, the United Kingdom, Switzerland, Brazil, and Australia, the Group's ingredients division has a portfolio of products with over 500 references and specialities in the food, cosmetics and pharma sectors and a sales network with presence in over 65 countries, with commercial offices in Australia and Asia. Regarding its clients, the company supplies to over 1,000 companies, among which, 8 of the top-ten food producers worldwide.

Natraceutical Group's 2007 figures were of 158.6 million euros in sales and 19.2 million euros in Ebitda.

Natraceutical is traded in the Spanish Stock Exchange under the ticker **NTC**.

Outstanding shares: 328,713,946

www.natraceuticalgroup.com



For more information

Media

Madrid

Ignacio Berckemeyer
Porter Novelli España
Tel. (+34) 91 702 73 00
Móvil: (+34) 699 32 06 23
E-mail: ignacio.berckemeyer@porternovelli.es

Valencia

Maite Ruiz
Porter Novelli España
Tel. (+34) 96 394 39 42
Móvil: (+34) 690 82 06 46
E-mail: maite.ruiz@porternovelli.es

Investors

Glòria Folch
Dir. Investors Relations and Communication
Tel. (+34) 93 584 81 87
E-mail: gloria.folch@natraceuticalgroup.com